Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

MXCT vs LNTH vs RMD vs BTBT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MXCT
MaxCyte, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$93M
5Y Perf.-94.9%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+247.7%
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.15B
5Y Perf.-23.9%
BTBT
Bit Digital, Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$589M
5Y Perf.-79.7%

MXCT vs LNTH vs RMD vs BTBT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MXCT logoMXCT
LNTH logoLNTH
RMD logoRMD
BTBT logoBTBT
IndustryMedical - DevicesDrug Manufacturers - Specialty & GenericMedical - Instruments & SuppliesFinancial - Capital Markets
Market Cap$93M$5.92B$30.15B$589M
Revenue (TTM)$33M$1.55B$5.54B$164M
Net Income (TTM)$-45M$279M$1.52B$137M
Gross Margin81.2%60.5%61.7%61.9%
Operating Margin-138.3%18.8%34.3%16.8%
Forward P/E17.5x18.8x9.2x
Total Debt$18M$738K$852M$14M
Cash & Equiv.$20M$359M$1.21B$95M

MXCT vs LNTH vs RMD vs BTBTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MXCT
LNTH
RMD
BTBT
StockJul 21May 26Return
MaxCyte, Inc. (MXCT)1005.1-94.9%
Lantheus Holdings, … (LNTH)100347.7+247.7%
ResMed Inc. (RMD)10076.1-23.9%
Bit Digital, Inc. (BTBT)10020.3-79.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: MXCT vs LNTH vs RMD vs BTBT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BTBT leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Lantheus Holdings, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. RMD also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MXCT
MaxCyte, Inc.
The Secondary Option

MXCT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.

  • 41.9% 10Y total return vs RMD's 293.8%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
  • Beta 0.47 vs BTBT's 3.37, lower leverage
  • +13.1% vs MXCT's -68.2%
Best for: long-term compounding and sleep-well-at-night
RMD
ResMed Inc.
The Income Pick

RMD is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 14 yrs, beta 0.66, yield 1.0%
  • Beta 0.66, yield 1.0%, current ratio 3.44x
  • 27.4% margin vs MXCT's -135.1%
  • 1.0% yield, 14-year raise streak, vs BTBT's 0.3%, (2 stocks pay no dividend)
Best for: income & stability and defensive
BTBT
Bit Digital, Inc.
The Banking Pick

BTBT carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 264.6%, EPS growth 225.0%
  • 264.6% NII/revenue growth vs MXCT's -14.5%
  • Lower P/E (9.2x vs 18.8x)
  • 19.0% ROA vs MXCT's -20.6%, ROIC 6.5% vs -18.7%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBTBT logoBTBT264.6% NII/revenue growth vs MXCT's -14.5%
ValueBTBT logoBTBTLower P/E (9.2x vs 18.8x)
Quality / MarginsRMD logoRMD27.4% margin vs MXCT's -135.1%
Stability / SafetyLNTH logoLNTHBeta 0.47 vs BTBT's 3.37, lower leverage
DividendsRMD logoRMD1.0% yield, 14-year raise streak, vs BTBT's 0.3%, (2 stocks pay no dividend)
Momentum (1Y)LNTH logoLNTH+13.1% vs MXCT's -68.2%
Efficiency (ROA)BTBT logoBTBT19.0% ROA vs MXCT's -20.6%, ROIC 6.5% vs -18.7%

MXCT vs LNTH vs RMD vs BTBT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MXCTMaxCyte, Inc.
FY 2024
Product
94.9%$21M
Product and Service, Other
5.1%$1M
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M
BTBTBit Digital, Inc.
FY 2024
Other Member
100.0%$550,260

MXCT vs LNTH vs RMD vs BTBT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGBTBT

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 4 of 6 comparable metrics.

RMD is the larger business by revenue, generating $5.5B annually — 167.7x MXCT's $33M. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to MXCT's -135.1%. On growth, RMD holds the edge at +10.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
RevenueTrailing 12 months$33M$1.5B$5.5B$164M
EBITDAEarnings before interest/tax-$41M$347M$2.1B$166M
Net IncomeAfter-tax profit-$45M$279M$1.5B$137M
Free Cash FlowCash after capex-$36M$372M$1.8B-$448M
Gross MarginGross profit ÷ Revenue+81.2%+60.5%+61.7%+61.9%
Operating MarginEBIT ÷ Revenue-138.3%+18.8%+34.3%+16.8%
Net MarginNet income ÷ Revenue-135.1%+18.0%+27.4%+17.3%
FCF MarginFCF ÷ Revenue-109.5%+24.0%+31.7%-65.3%
Rev. Growth (YoY)Latest quarter vs prior year-16.0%+1.2%+10.8%
EPS Growth (YoY)Latest quarter vs prior year0.0%+76.5%+9.3%+2.8%
RMD leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

MXCT leads this category, winning 3 of 6 comparable metrics.

At 9.2x trailing earnings, BTBT trades at a 66% valuation discount to LNTH's 26.7x P/E. On an enterprise value basis, BTBT's 8.5x EV/EBITDA is more attractive than RMD's 15.5x.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
Market CapShares × price$93M$5.9B$30.1B$589M
Enterprise ValueMkt cap + debt − cash$91M$5.6B$29.8B$508M
Trailing P/EPrice ÷ TTM EPS-2.08x26.69x21.76x9.15x
Forward P/EPrice ÷ next-FY EPS est.17.52x18.78x
PEG RatioP/E ÷ EPS growth rate1.25x
EV / EBITDAEnterprise value multiple14.61x15.51x8.49x
Price / SalesMarket cap ÷ Revenue2.81x3.84x5.86x3.60x
Price / BookPrice ÷ Book value/share0.54x5.72x5.11x0.56x
Price / FCFMarket cap ÷ FCF16.73x18.14x
MXCT leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — LNTH and RMD each lead in 4 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-24 for MXCT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RMD's 0.14x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs MXCT's 2/9, reflecting strong financial health.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
ROE (TTM)Return on equity-24.1%+24.3%+24.4%+21.4%
ROA (TTM)Return on assets-20.6%+12.4%+18.0%+19.0%
ROICReturn on invested capital-18.7%+30.6%+22.8%+6.5%
ROCEReturn on capital employed-22.2%+17.1%+25.7%+8.5%
Piotroski ScoreFundamental quality 0–92586
Debt / EquityFinancial leverage0.10x0.00x0.14x0.03x
Net DebtTotal debt minus cash-$2M-$358M-$358M-$81M
Cash & Equiv.Liquid assets$20M$359M$1.2B$95M
Total DebtShort + long-term debt$18M$738,000$852M$14M
Interest CoverageEBIT ÷ Interest expense11.72x66.06x
Evenly matched — LNTH and RMD each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $513 for MXCT. Over the past 12 months, LNTH leads with a +13.1% total return vs MXCT's -68.2%. The 3-year compound annual growth rate (CAGR) favors LNTH at -1.4% vs MXCT's -43.1% — a key indicator of consistent wealth creation.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
YTD ReturnYear-to-date-43.8%+35.3%-15.2%-10.3%
1-Year ReturnPast 12 months-68.2%+13.1%-14.5%-9.0%
3-Year ReturnCumulative with dividends-81.6%-4.0%-8.4%-19.7%
5-Year ReturnCumulative with dividends-94.9%+314.2%+11.0%-84.6%
10-Year ReturnCumulative with dividends-94.9%+4192.5%+293.8%-60.4%
CAGR (3Y)Annualised 3-year return-43.1%-1.4%-2.9%-7.1%
LNTH leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LNTH leads this category, winning 2 of 2 comparable metrics.

LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than BTBT's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs MXCT's 30.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
Beta (5Y)Sensitivity to S&P 5001.44x0.47x0.66x3.37x
52-Week HighHighest price in past year$2.86$93.00$293.81$4.55
52-Week LowLowest price in past year$0.66$47.25$198.64$1.25
% of 52W HighCurrent price vs 52-week peak+30.5%+97.8%+70.4%+40.2%
RSI (14)Momentum oscillator 0–10052.261.235.669.1
Avg Volume (50D)Average daily shares traded847K886K1.1M18.5M
LNTH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

RMD leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: LNTH as "Buy", RMD as "Buy", BTBT as "Buy". Consensus price targets imply 173.2% upside for BTBT (target: $5) vs 11.0% for LNTH (target: $101). For income investors, RMD offers the higher dividend yield at 1.02% vs BTBT's 0.31%.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.BTBT logoBTBTBit Digital, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$101.00$281.29$5.00
# AnalystsCovering analysts17352
Dividend YieldAnnual dividend ÷ price+1.0%+0.3%
Dividend StreakConsecutive years of raises0140
Dividend / ShareAnnual DPS$2.11$0.01
Buyback YieldShare repurchases ÷ mkt cap+0.2%+5.1%+1.0%0.0%
RMD leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

RMD leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). LNTH leads in 2 (Total Returns, Risk & Volatility). 1 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 2 of 6 categories
Loading custom metrics...

MXCT vs LNTH vs RMD vs BTBT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MXCT or LNTH or RMD or BTBT a better buy right now?

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -14. 5% for MaxCyte, Inc. (MXCT). Bit Digital, Inc. (BTBT) offers the better valuation at 9. 2x trailing P/E, making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MXCT or LNTH or RMD or BTBT?

On trailing P/E, Bit Digital, Inc.

(BTBT) is the cheapest at 9. 2x versus Lantheus Holdings, Inc. at 26. 7x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 17. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — MXCT or LNTH or RMD or BTBT?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MXCT's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MXCT or LNTH or RMD or BTBT?

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Bit Digital, Inc. 's 3. 37β — meaning BTBT is approximately 618% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 14% for ResMed Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — MXCT or LNTH or RMD or BTBT?

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -14. 5% for MaxCyte, Inc. (MXCT). On earnings-per-share growth, the picture is similar: Bit Digital, Inc. grew EPS 225. 0% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MXCT or LNTH or RMD or BTBT?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -135. 1% for MaxCyte, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -138. 3% for MXCT. At the gross margin level — before operating expenses — MXCT leads at 81. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MXCT or LNTH or RMD or BTBT more undervalued right now?

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 17. 5x forward P/E versus 18. 8x for ResMed Inc. — 1. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BTBT: 173. 2% to $5. 00.

08

Which pays a better dividend — MXCT or LNTH or RMD or BTBT?

In this comparison, RMD (1.

0% yield), BTBT (0. 3% yield) pay a dividend. MXCT, LNTH do not pay a meaningful dividend and should not be held primarily for income.

09

Is MXCT or LNTH or RMD or BTBT better for a retirement portfolio?

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RMD: +293. 8%, BTBT: -60. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MXCT and LNTH and RMD and BTBT?

These companies operate in different sectors (MXCT (Healthcare) and LNTH (Healthcare) and RMD (Healthcare) and BTBT (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MXCT is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock; BTBT is a small-cap high-growth stock. RMD pays a dividend while MXCT, LNTH, BTBT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MXCT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 48%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Stocks Like

BTBT

High-Growth Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 132%
  • Net Margin > 10%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MXCT and LNTH and RMD and BTBT on the metrics below

Revenue Growth>
%
(MXCT: -16.0% · LNTH: 1.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.